Altimmune (NASDAQ:ALT) Stock Price Up 6.5%

Altimmune, Inc. (NASDAQ:ALT - Get Free Report) shares traded up 6.5% during trading on Monday . The company traded as high as $7.37 and last traded at $7.36. 1,032,095 shares were traded during trading, a decline of 81% from the average session volume of 5,444,214 shares. The stock had previously closed at $6.91.

Analysts Set New Price Targets

A number of research analysts have recently commented on the company. B. Riley reaffirmed a "buy" rating and set a $20.00 target price on shares of Altimmune in a research note on Thursday, March 28th. The Goldman Sachs Group assumed coverage on Altimmune in a report on Wednesday, January 24th. They issued a "neutral" rating and a $13.00 price target for the company. Finally, HC Wainwright lowered their price target on Altimmune from $15.00 to $12.00 and set a "buy" rating for the company in a report on Monday, April 1st.

Altimmune Stock Performance

The firm has a fifty day moving average price of $9.41 and a 200 day moving average price of $7.46. The stock has a market cap of $529.55 million, a PE ratio of -4.53 and a beta of 0.05.

Altimmune (NASDAQ:ALT - Get Free Report) last issued its quarterly earnings data on Wednesday, March 27th. The company reported ($0.33) EPS for the quarter, beating the consensus estimate of ($0.35) by $0.02. Altimmune had a negative return on equity of 44.77% and a negative net margin of 20,780.75%. The firm had revenue of $0.04 million during the quarter. On average, equities research analysts forecast that Altimmune, Inc. will post -1.52 earnings per share for the current year.

Institutional Trading of Altimmune

Several hedge funds and other institutional investors have recently made changes to their positions in the business. FNY Investment Advisers LLC acquired a new stake in Altimmune during the 4th quarter worth about $35,000. Russell Investments Group Ltd. grew its position in Altimmune by 1,150.9% during the 4th quarter. Russell Investments Group Ltd. now owns 4,303 shares of the company's stock worth $48,000 after purchasing an additional 3,959 shares during the period. EWG Elevate Inc. grew its position in Altimmune by 50.0% during the 4th quarter. EWG Elevate Inc. now owns 15,000 shares of the company's stock worth $169,000 after purchasing an additional 5,000 shares during the period. Horizon Wealth Management LLC acquired a new stake in Altimmune during the 4th quarter worth about $112,000. Finally, Deuterium Capital Management LLC acquired a new stake in Altimmune during the 4th quarter worth about $112,000. Hedge funds and other institutional investors own 78.05% of the company's stock.

About Altimmune

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.